Solvay licenses MediTECH® to fulfill orders for Zeniva® PEEK shapes

Alpharetta, Ga., Oct. 14, 2019 --- Solvay announces a new licensing agreement with MediTECH®, a division of Mitsubishi Chemical Advanced Materials. The agreement allows MediTECH® to fulfill customer orders for extruded polymer shapes made with Solvay’s Zeniva® polyetheretherketone (PEEK), a high-performance, biocompatible polymer used primarily for orthopedic, cardiac and neurological implants. Effective immediately, MediTECH® will become Solvay’s licensee for global fulfillment of Zeniva® PEEK shapes. Solvay’s intent is to transfer all fulfillment activities to MediTECH®.

Mitsubishi Chemical Advanced Materials has manufactured Solvay’s Zeniva® PEEK shapes since the material’s inception 12 years ago. The new licensing agreement expands MediTECH’s® existing role in the longstanding partnership between the two companies, with the goal of now bringing additional services and benefits to customers. First, MediTECH® will supply customers with Solvay’s current product line of Zeniva® PEEK extruded rods and plates. Secondly, the company plans to offer new, innovative near net Zeniva® PEEK shapes to the market. Finally, by adding Zeniva® PEEK shapes to its existing, complementary portfolio of implantable ultra-high molecular weight polyethylene (UHMW-PE) shapes, MediTECH® aims to simplify the entire supply chain for all customers.  

“The addition of Zeniva® PEEK shapes coupled with our unique near net manufacturing technology can provide customers with productivity improvements and a simplified supply chain,” says Eric Tech, global market manager for the Medical industry at Mitsubishi Chemical Advanced Materials.

For more than 30 years, the MediTECH® Division of Mitsubishi Chemical Advanced Materials has supplied leading orthopedic implant manufacturers with premium implantable-grade UHMW-PE under the Chirulen® and Extrulen® brand names. The company’s manufacturing facilities are certified under ISO 13485.

This licensing agreement underscores our commitment to make it easier for customers to do business with Solvay and our partners,” said Jeff Hrivnak, global business manager for Healthcare at Solvay’s Specialty Polymers global business unit. “By reassigning fulfillment activities to MediTECH® our customers will further benefit from the company’s extensive expertise in regulatory requirements and polymer shape technologies.”

Zeniva® PEEK has a modulus very close to that of cortical bone, plus excellent fatigue resistance and toughness. In addition, it offers numerous advantages over metals, such as a reduction of stress shielding, no heavy metal allergy or ion erosion, and offers radiolucent properties, which allow x-ray and CT scanning procedures without interference.

®Zeniva is a registered trademark of Solvay.

®MediTECH, Chirulen and Extrulen are registered trademarks of Mitsubishi Chemical Advanced Materials group.

About Mitsubishi Chemical Advanced Materials

With more than 80 years of experience, 30 branch offices in 20 countries, and a team of technical service experts, engineers, and application development managers, Mitsubishi Chemical Advanced Materials* is the global leader for researching, developing, and manufacturing high-performance engineered polymer materials. Our products make the world a safer place by providing solutions across all industries, including food processing and packaging, aerospace and defense, semiconductor, oil and gas, medical and life sciences, renewable energy, construction and heavy equipment, and electronics. Learn more at www.mcam.com.

About MediTECH®

For more than 30 years, Mitsubishi Chemical Advanced Materials' MediTECH® Division has supplied leading orthopedic implant manufacturers with premium implantable-grade UHMW-PE under the Chirulen® and Extrulen® brand names. Due to their superior physical and mechanical properties, cleanliness and consistency, they have become the materials of choice for helping restore a higher quality of life to millions of patients worldwide.

*Mitsubishi Chemical Advanced Materials, formerly Quadrant EPP, was officially named on April 1, 2019. The Quadrant Group was established in 2001 and acquired by Mitsubishi Chemical Corporation in 2013.

Solvay is an advanced materials and specialty chemicals company, committed to developing chemistry that addresses key societal challenges. Solvay innovates and partners with customers worldwide in many diverse end markets. Its products are used in planes, cars, batteries, smart and medical devices, as well as in mineral and oil and gas extraction, enhancing efficiency and sustainability. Its lightweighting materials promote cleaner mobility, its formulations optimize the use of resources and its performance chemicals improve air and water quality. Solvay is headquartered in Brussels with around 24,500 employees in 61 countries. Net sales were €10.3 billion in 2018, with 90% from activities where Solvay ranks among the world's top 3 leaders, resulting in an EBITDA margin of 22%. Solvay SA (SOLB.BE) is listed on Euronext Brussels and Paris Bloomberg: SOLB.BB - Reuters: SOLB.BR), and in the United States its shares (SOLVY) are traded through a level-1 ADR program. Financial figures take into account the planned divestment of Polyamides.

Solvay Specialty Polymers manufactures over 1500 products across 35 brands of high-performance polymers – fluoropolymers, fluoroelastomers, fluorinated fluids, semi-aromatic polyamides, sulfone polymers, ultra-high performance aromatic polymers, and high‑barrier polymers – for use in Aerospace, Alternative Energy, Automotive, Healthcare, Membranes, Oil & Gas, Packaging, Plumbing, Semiconductors, Wire & Cable, and other industries. Learn more at www.solvayspecialtypolymers.com.